checkAd

     480  0 Kommentare Sanofi and Regeneron Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® (alirocumab) Injection Fully Enrolled - Seite 2

    In September, the European Commission approved the marketing authorization for Praluent. In the E.U., Praluent is approved for the treatment of adult patients with primary hypercholesterolemia (HeFH and non-familial) or mixed dyslipidemia as an adjunct to diet: a) in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach their LDL cholesterol goals with the maximally-tolerated statin or b) alone or in combination with other lipid-lowering therapies for patients who are statin intolerant, or for whom a statin is contraindicated. The effect of Praluent on CV morbidity and mortality has not yet been determined.

    This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Sanofi S.A.!
    Long
    80,01€
    Basispreis
    0,99
    Ask
    × 8,93
    Hebel
    Short
    99,53€
    Basispreis
    1,06
    Ask
    × 8,43
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Important Safety Information for U.S.
    Do not use PRALUENT if you are allergic to alirocumab or to any of the ingredients in PRALUENT.
    Before you start using PRALUENT, tell your healthcare provider about all your medical conditions, including allergies, and if you are pregnant or plan to become pregnant or if you are breastfeeding or plan to breastfeed.

    Tell your healthcare provider or pharmacist about any prescription and over-the-counter medicines you are taking or plan to take, including natural or herbal remedies.

    PRALUENT can cause serious side effects, including allergic reactions that can be severe and require treatment in a hospital. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any symptoms of an allergic reaction including a severe rash, redness, severe itching, a swollen face, or trouble breathing.

    The most common side effects of PRALUENT include: redness, itching, swelling, or pain/tenderness at the injection site, symptoms of the common cold, and flu or flu-like symptoms. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

    Talk to your doctor about the right way to prepare and give yourself a PRALUENT injection and follow the "Instructions for Use" that comes with Praluent.

    You are encouraged to report negative side effects of prescription drugs to the FDA.

    Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

    Please click here for the full Prescribing Information

    About Sanofi
    Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

    Seite 2 von 5


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Sanofi and Regeneron Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® (alirocumab) Injection Fully Enrolled - Seite 2 Sanofi and Regeneron Announce 18,000-Patient ODYSSEY OUTCOMESTrial of Praluent® (alirocumab) Injection Fully Enrolled Paris and Tarrytown, New York - November 24, 2015 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the …

    Schreibe Deinen Kommentar

    Disclaimer